Skip to main content
. 2017 Feb 28;8(14):23702–23712. doi: 10.18632/oncotarget.15784

Figure 4. Treatment response to evofosfamide and irradiation in vitro.

Figure 4

(A) Proliferation of A549 lung adenocarcinoma cells in response to increasing doses of evofosfamide. Cells were pre-incubated in hypoxia (0.2% O2) for 23 hours, followed by treatment with increasing concentrations of evofosfamide under hypoxic conditions for 1 hour (left panel). Proliferation of A549 cells pre-incubated for 23, 18 and 2h in hypoxia (0.2% O2), followed by treatment with evofosfamide (0.5 μM) under hypoxia for 1, 6 and 22 hours, respectively (right panel). The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) To determine time-dependent effects of evofosfamide, cells were incubated for 23, 18 and 2h in hypoxia (0.2% O2), followed by treatment with evofosfamide (0.5 μM) for 1, 6 and 22 hours, respectively. The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) Clonogenic cell survival assay of A549 cells treated with 0.5 μM evofosfamide under normoxic (21% O2) and hypoxic (0.2% O2) conditions for 4 hours. Following reoxygenation, cells were irradiated with increasing doses of IR. (C) Clonogenic survival assay of lung carcinoma A549 cells irradiated with 2 Gy and treated thereafter with evofosfamide (0.5 μM) under normoxic (21% O2) and hypoxic (0.2% O2) conditions for 4 hours (adjuvant setting); Error bars represent SEM.